Study wrapper · #215
The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency.
Editor's note
This is medicinal-chemistry work, not a biological efficacy study: the researchers used ipamorelin as a structural reference point while designing more potent growth-hormone secretagogues based on the compound NN703. By adding polar, conformationally constrained amine groups to NN703's C-terminus, they produced analogues with low-nanomolar in-vitro potency and improved drug-like properties, including 40% oral bioavailability, with the best compound raising growth hormone above 40 ng/mL in a single-dose pig study. Ipamorelin itself is not the subject — it anchors a structure-activity comparison. For readers interested in ipamorelin, the value is narrow context: it situates ipamorelin within a family of secretagogues being optimised for potency and oral delivery. There are no human data, no clinical endpoints, and no safety information for people; the work is in-vitro plus a single pig experiment. Treat it as chemistry, not as evidence bearing on ipamorelin's clinical use. Human studies would be required for any therapeutic conclusion.
Plain-language abstract
This is a drug-design (chemistry) study aimed at building more potent compounds that make the body release growth hormone. The researchers compared two known growth-hormone-releasing compounds — ipamorelin and NN703 — and used that comparison to guide changes to NN703's structure, specifically adding a polar chemical group at one end of the molecule. They tested a series of modified compounds and found that certain rigid, nitrogen-containing groups produced the strongest activity in laboratory assays, working at very low concentrations. One promising modification also gave good drug-like properties, such as 40% of the dose being absorbed when taken by mouth. The most promising compound was then tested in a single dose in pigs, where it raised growth-hormone levels above 40 nanograms per millilitre. Ipamorelin was used mainly as a reference to guide the chemistry. This is early laboratory and animal work about designing molecules; it does not study whether ipamorelin or the new compounds benefit or harm people, and reports no human results or side effects.